Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 7, 2009, Pages 1358-1370

  Chen, Tao ^a   Li, Mian ^a   Zhang, Ruiwen ^b   Wang, Hui ^a  

^a INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Apoptosis; Artemisinin; Chemotherapy; Dihydroartemisinin; Ovarian cancer

Indexed keywords

ARTEMISININ DERIVATIVE; CARBOPLATIN; CYTOCHROME C; DIHYDROARTEMISININ;

APOPTOSIS; ARTICLE; BIOLOGICAL MODEL; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECT; DRUG SCREENING; FEMALE; HUMAN; METABOLISM; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; ARTEMISININS; CARBOPLATIN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYTOCHROMES C; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIAL MEMBRANES; MODELS, BIOLOGICAL; OVARIAN NEOPLASMS;

EID: 68149173166     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00360.x     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007 57 : 43 66.
2. Colombo N, Van Gorp T, Parma G, et al. Ovarian cancer. Crit Rev Oncol Hematol. 2006 60 : 159 79.
3. Mutch DG. Gemcitabine combination chemotherapy of ovarian cancer. Gynecol Oncol. 2003 90 : S16 20.
4. Johnston SR. Ovarian cancer: review of the National Institute for Clinical Excellence (NICE) guidance recommendations. Cancer Invest. 2004 22 : 730 42.
5. Sorenson CM, Eastman A. Mechanism of cis-diamminedichloroplatinum(II)- induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res. 1988 48 : 4484 8.
6. Pavelka M, Lucas MF, Russo N. On the hydrolysis mechanism of the second-generation anticancer drug carboplatin. Chemistry. 2007 13 : 10108 16.
7. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003 3 : 502 16.
8. Klayman DL. Qinghaosu (artemisinin): an antimalarial drug from China. Science. 1985 228 : 1049 55.
9. Singh NP, Lai H. Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci. 2001 70 : 49 56.
10. Borstnik K, Paik IH, Shapiro TA, Posner GH. Antimalarial chemotherapeutic peroxides: artemisinin, yingzhaosu A and related compounds. Int J Parasitol. 2002 32 : 1661 7.
11. May WS Jr., Cuatrecasas P. Transferrin receptor: its biological significance. J Membr Biol. 1985 88 : 205 15.
12. Moore JC, Lai H, Li JR, et al. Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat. Cancer Lett. 1995 98 : 83 7.
13. Lai H, Singh NP. Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. Cancer Lett. 1995 91 : 41 6.
14. Beekman AC, Wierenga PK, Woerdenbag HJ, et al. Artemisinin-derived sesquiter pene lactones as potential antitumour compounds: cytotoxic action against bone marrow and tumour cells. Planta Med. 1998 64 : 615 9.
15. Posner GH, Ploypradith P, Parker MH, et al. Antimalarial, antiproliferative, and antitumor activities of artemisinin-derived, chemically robust, trioxane dimers. J Med Chem. 1999 42 : 4275 80.
16. Efferth T, Dunstan H, Sauerbrey A, et al. The anti-malarial artesunate is also active against cancer. Int J Oncol. 2001 18 : 767 73.
17. Chen HH, Zhou HJ, Fang X. Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. Pharmacol Res. 2003 48 : 231 6.
18. Lai H, Sasaki T, Singh NP, Messay A. Effects of artemisinin-tagged holotransferrin on cancer cells. Life Sci. 2005 76 : 1267 79.
19. Lai H, Singh NP. Oral artemisinin prevents and delays the development of 7,12-dimethylbenz[a]anthracene (DMBA) induced breast cancer in the rat. Cancer Lett. 2006 231 : 43 8.
20. Singh NP, Lai HC. Artemisinin induces apoptosis in human cancer cells. Anticancer Res. 2004 24 : 2277 80.
21. Disbrow GL, Baege AC, Kierpiec KA, et al. Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo. Cancer Res. 2005 65 : 10854 61.
22. Lee J, Zhou HJ, Wu XH. Dihydroartemisinin downregulates vascular endothelial growth factor expression and induces apoptosis in chronic myeloid leukemia K562 cells. Cancer Chemother Pharmacol. 2006 57 : 213 20.
23. Dell'Eva R, Pfeffer U, Vene R, et al. Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. Biochem Pharmacol. 2004 68 : 2359 66.
24. Efferth T, Olbrich A, Bauer R. mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether. Biochem Pharmacol. 2002 64 : 617 23.
25. Efferth T, Sauerbrey A, Olbrich A, et al. Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol. 2003 64 : 382 94.
26. Aldieri E, Atragene D, Bergandi L, et al. Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF-kB activation. FEBS Lett. 2003 552 : 141 4.
27. Efferth T. Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. Curr Drug Targets. 2006 7 : 407 21.
28. Wu XH, Zhou HJ, Lee J. Dihydroartemisinin inhibits angiogenesis induced by multiple myeloma RPMI8226 cells under hypoxic conditions via downregulation of vascular endothelial growth factor expression and suppression of vascular endothelial growth factor secretion. Anticancer Drugs. 2006 17 : 839 48.
29. Li Y, Shan F, Wu JM, et al. Novel antitumor artemisinin derivatives targeting G1 phase of the cell cycle. Bioorg Med Chem Lett. 2001 11 : 5 8.
30. Lin F, Qian ZY, Xue HW, et al. Comparison of inhibitory effects between artemisinin and artemisunate on proliferation of MCF-7 cells in vitro. Chin Tra dit Herb Drugs. 2003 34 : 347 9.
31. Wu JM, Shan F, Wu GS, et al. synthesis and cytotoxicity of artemisinin derivatives containing cyanoarylmethyl group. Eur J Med Chem. 2001 36 : 469 79.
32. Chen HH, Zhou HJ, Wu GD, Lou XE. Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1. Pharmacology. 2004 71 : 1 9.
33. Chen HH, Zhou HJ, Wang WQ, Wu GD. Antimalarial dihydroartemisinin also inhibits angiogenesis. Cancer Chemother Pharmacol. 2004 53 : 423 32.
34. Jung M, Tak J, Chung WY, Park KK. Antiangiogenic activity of deoxoartemisinin derivatives on chorioallantoic membrane. Bioorg Med Chem Lett. 2006 16 : 1227 30.
35. Wang H, Nan L, Yu D, et al. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Clin Cancer Res. 2001 7 : 3613 24.
36. Wang H, Rayburn E, Wang W, et al. Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharma-cokinetics, in vitro and in vivo anti-cancer activity and potentiation of antibody therapy. Mol Cancer Ther. 2006 5 : 2106 14.
37. Zhang Z, Li M, Wang H, et al. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci USA. 2003 100 : 11636 41.
38. Zhang Z, Wang H, Li M, et al. MDM2 is a negative regulator of p21 WAF1/CIP1, independent of p53. J Biol Chem. 2004 279 : 16000 6.
39. Zhang Z, Wang H, Li M, et al. Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene. 2005 24 : 7238 47.
40. Wang H, Cai Q, Zeng X, et al. Anti-tumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to RI. subunit of protein kinase A after oral administration. Proc Natl Acad Sci USA. 1999 96 : 13989 94.
41. Wang H, Li M, Rinehart JJ, Zhang R. Pretreatment with dexamethasone increases anti-tumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics and clinical implications for cancer chemotherapy. Clin Cancer Res. 2004 10 : 1633 44.
42. Sadava D, Phillips T, Lin C, Kane SE. Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells. Cancer Lett. 2002 179 : 151 6.
43. Kim SJ, Kim MS, Lee JW, et al. Dihydroartemisinin enhances radiosensitivity of human glioma cells in vitro. J Cancer Res Clin Oncol. 2006 132 : 129 35.
44. Jiao Y, Ge CM, Meng QH, et al. Dihydroartemisinin is an inhibitor of ovarian cancer cell growth. Acta Pharmacol Sin. 2007 28 : 1045 56.
45. Hengartner MO. The biochemistry of apoptosis. Nature. 2000 407 : 770 6.
46. Hu W, Kavanagh JJ. Anticancer therapy targeting the apoptotic pathway. Lancet Oncol. 2003 4 : 721 9.
47. Isoldi MC, Visconti MA, Castrucci AM. Anti-cancer drugs: molecular mechanisms of action. Mini Rev Med Chem. 2005 5 : 685 95.
48. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 1999 13 : 1899 911.